Athira Pharma to Present at Stifel 2022 Healthcare Conference
Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. Management will host a fireside chat on November 16 at 4:45 p.m. EST. Interested parties can access a live webcast through the Investors section of Athira's website, with an archived replay available for 30 days post-event. Athira aims to develop small molecules for conditions like Alzheimer's and Parkinson's disease, targeting the HGF/MET neurotrophic system.
Details
News Market Reaction – ATHA
The recorded move for ATHA in the trading session of this news was -7.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira’s management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City. Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.
A live webcast of the fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcast will be available for at least 30 days following the event.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.